[Medical care situation of patients with ankylosing spondylitis and psoriatic arthritis in Germany : Medical care situation of patients with spondyloarthritis (SpA): ankylosing spondylitis (AS) and psoriatic arthritis (PsA) from the perspective of rheumatologists in private practice and hospitals in Germany-Results of the research project "SpA Loop-Life of Outpatients"].
Versorgungssituation von Patienten mit ankylosierender Spondylitis und Psoriasisarthritis in Deutschland : Versorgungssituation von Patienten mit Spondyloarthritis (SpA): Ankylosierende Spondylitis (AS) und Psoriasisarthritis (PsA) aus der Sicht von niedergelassenen und in Kliniken tätigen Rheumatologen in Deutschland – Ergebnisse des Forschungsprojekts „SpA Loop – Life of Outpatients“.
Diagnosis
Disease activity
Patient care
Rheumatology
Treatment adaptation
Journal
Zeitschrift fur Rheumatologie
ISSN: 1435-1250
Titre abrégé: Z Rheumatol
Pays: Germany
ID NLM: 0414162
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
pubmed:
16
3
2019
medline:
8
10
2019
entrez:
16
3
2019
Statut:
ppublish
Résumé
The prevalence of spondyloarthritis (SpA) in Germany is approximately 1-1.4% and includes predominantly axial SpA (axSpA) and predominantly peripheral SpA. Ankylosing spondylitis (AS) belongs to the group of axial SpA but also exhibits peripheral manifestations. Psoriatic arthritis (PsA) can show purely peripheral or also axial manifestations. The total prevalence of SpA in Germany is approximately 1‑1.4%, the prevalence of AS is ca. 0.5% and PsA 0.2-1.4%. Patients with AS are mainly treated by internal medical rheumatologists but in many places also basically treated by general practitioners and orthopedists. Patients with PsA are mainly diagnosed and treated by rheumatologists and dermatologists working in private practice or in clinical settings. Besides the control of inflammatory activity and prevention or slowing down of the characteristic disease progression, including irreversible structural changes, the main objectives of patients as well as treating physicians are particularly freedom from pain and a quality of life comparable to non-affected persons. Decisive for successful treatment are an early diagnosis and initiation of adequate therapy as well as regular monitoring of disease activity including treatment adjustment taking the needs of the patient into consideration; however, it is unknown how often this is actually successful in routine daily practice in Germany. The aim of the SpA Loop research project was to display the current medical care situation of patients with AS and PsA treated in private practices and hospitals for rheumatology in Germany focusing on patient/physician profiles as well as the diagnostics and treatment. The instrument for the survey was a standardized questionnaire with 29 multiple choice and perception questions that was distributed to medical specialists in the field of internal medicine and rheumatology. A high accordance between rheumatologists in private practice and in hospitals was observed with respect to the presentation and perception of the current medical care situation for patients with AS and PsA in Germany. Differences were only occasionally found. The results of this research project reflect the current status of the medical care situation of AS and PsA patients in Germany. They provide information on which areas of the medical care situation can selectively be improved as well as on interesting aspects and points of discussion with respect to the patient population treated.
Sections du résumé
BACKGROUND
BACKGROUND
The prevalence of spondyloarthritis (SpA) in Germany is approximately 1-1.4% and includes predominantly axial SpA (axSpA) and predominantly peripheral SpA. Ankylosing spondylitis (AS) belongs to the group of axial SpA but also exhibits peripheral manifestations. Psoriatic arthritis (PsA) can show purely peripheral or also axial manifestations. The total prevalence of SpA in Germany is approximately 1‑1.4%, the prevalence of AS is ca. 0.5% and PsA 0.2-1.4%. Patients with AS are mainly treated by internal medical rheumatologists but in many places also basically treated by general practitioners and orthopedists. Patients with PsA are mainly diagnosed and treated by rheumatologists and dermatologists working in private practice or in clinical settings. Besides the control of inflammatory activity and prevention or slowing down of the characteristic disease progression, including irreversible structural changes, the main objectives of patients as well as treating physicians are particularly freedom from pain and a quality of life comparable to non-affected persons. Decisive for successful treatment are an early diagnosis and initiation of adequate therapy as well as regular monitoring of disease activity including treatment adjustment taking the needs of the patient into consideration; however, it is unknown how often this is actually successful in routine daily practice in Germany.
OBJECTIVE
OBJECTIVE
The aim of the SpA Loop research project was to display the current medical care situation of patients with AS and PsA treated in private practices and hospitals for rheumatology in Germany focusing on patient/physician profiles as well as the diagnostics and treatment.
MATERIAL AND METHODS
METHODS
The instrument for the survey was a standardized questionnaire with 29 multiple choice and perception questions that was distributed to medical specialists in the field of internal medicine and rheumatology.
RESULTS
RESULTS
A high accordance between rheumatologists in private practice and in hospitals was observed with respect to the presentation and perception of the current medical care situation for patients with AS and PsA in Germany. Differences were only occasionally found.
CONCLUSION
CONCLUSIONS
The results of this research project reflect the current status of the medical care situation of AS and PsA patients in Germany. They provide information on which areas of the medical care situation can selectively be improved as well as on interesting aspects and points of discussion with respect to the patient population treated.
Identifiants
pubmed: 30874934
doi: 10.1007/s00393-019-0619-6
pii: 10.1007/s00393-019-0619-6
doi:
Types de publication
Journal Article
Langues
ger
Sous-ensembles de citation
IM
Pagination
372-381Références
Z Rheumatol. 2004 Jun;63(3):193-202
pubmed: 15224222
Arthritis Rheum. 2005 Dec;52(12):4048-9; author reply 4049-50
pubmed: 16320356
J Rheumatol. 2007 Jan;34(1):5-7
pubmed: 17216671
Clin Exp Rheumatol. 2013 Nov-Dec;31(6):992
pubmed: 24237935
Clin Exp Rheumatol. 2015 Sep-Oct;33(5 Suppl 93):S55-9
pubmed: 26472605
Z Rheumatol. 2016 May;75(4):346-53
pubmed: 27142379
Expert Rev Clin Immunol. 2016 Nov;12(11):1209-1215
pubmed: 27284965
Ann Rheum Dis. 2017 Jun;76(6):978-991
pubmed: 28087505
Ann Rheum Dis. 2017 Sep;76(9):1502-1508
pubmed: 28283515
Rheumatol Ther. 2017 Dec;4(2):219-231
pubmed: 28600789
Arthritis Rheum. 1998 Jan;41(1):58-67
pubmed: 9433870